Back

Serum sLOX-1 concentrations are associated with 2- year major adverse cardiovascular and cerebrovascular events in patients after percutaneous coronary intervention: A multicenter pilot study

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 2 - Acute Coronary Syndromes: Biomarkers Biomarkers ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Zi-Wen Zhao

Union Hospital, Fujian Medical University,, Fuzhou (China)

6 More presentations in this session

Presentation thumbnail
Novel biomarker algorithmic panel measuring permutations of immune response to cardiac endothelial injury and global risk factors identifies patients at risk of acute coronary syndrome (ACS)
Professor D. Harrington (Irvine, US)
Abstract Slides
Presentation thumbnail
Plasma proteomics in healthy individuals predict myocardial infarction
Ms R. Hoogeveen (Amsterdam, NL)
Abstract
Presentation thumbnail
The protein APRIL predicts adverse outcomes in DAPT patients better than NT-proBNP and troponin
Professor C. Pemberton (Christchurch, NZ)
Abstract
Presentation thumbnail
GLP-1 levels predict cardiovascular risk in patients with acute myocardial infarction
Doctor M. Lehrke (Aachen, DE)
Abstract
Presentation thumbnail
The novel small leucin-rich repeat protein podocan is an independent predictor of major adverse cardiac events in patients with angiographically-defined coronary artery disease
Doctor K. watthanasuntorn (Cooperstown, US)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 2 - Acute Coronary Syndromes: Biomarkers

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources